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Abstract
Background: Liver resection is commonly performed for malignant and benign disease and is associated with
frequent use of intraoperative and postoperative blood transfusions. Blood transfusions are potentially life-saving,
but they have many adverse effects; some well understood, and others less so. Some of the poorly understood side
effects include increased risk of postoperative complications and possibly worse oncologic outcomes. The objective
of this systematic review is to provide estimates of transfusion prevalence and the effects of perioperative blood
transfusion on postoperative mortality and morbidity and long-term cancer outcomes in patients undergoing liver
resection.
Methods/design: The Cochrane, Medline, and EMBASE databases will be searched for any randomized controlled
trial or observational cohort study comparing liver resection patients that received intraoperative or postoperative
allogeneic red blood cell transfusions to those who did not. Outcomes include postoperative mortality,
postoperative morbidity (infectious, liver failure, renal failure, cardiovascular/cerebrovascular events, and
thromboembolic events), and long-term disease-free and overall survival. Only studies with adult, human patients
(>18 years old) undergoing liver resection, in which the primary intervention of interest is blood transfusion will be
included. Data will be extracted by two reviewers in duplicate and synthesized into a narrative review. Risk of bias
will be assessed. When clinically and methodologically appropriate, meta-analysis will be performed.
Discussion: Our review will synthesize the literature pertaining to the potential beneficial and detrimental effects of
red blood cell transfusion in patients undergoing liver resection. It will be an important step in the development of
guidelines for the appropriate use of blood transfusions in patients undergoing liver resection.
Systematic review registration: PROSPERO CRD42015026132
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Background
Liver resection is a major intraabdominal surgery
performed for a number of indications, but most
commonly for removal of malignant neoplasms. The
liver receives approximately 25 % of the cardiac output
[1], and therefore resection is associated with moderate or
significant blood loss, at times life-threatening, and not
uncommonly results in the use of intraoperative or
postoperative blood transfusions. The loss of blood from
the intravascular space results in decreased oxygen-
carrying capacity and decreased delivery of oxygen to the
tissues; however, numerous physiologic adaptations occur
to cope with these changes. The amount of tolerable
blood loss is difficult to define precisely and is influenced
by individual patient and disease-related factors. The esti-
mation of surgical blood loss is also difficult, and many
different methods and calculations of blood loss have been
studied and described [2, 3]. Furthermore, the decision to
replace blood volume by way of blood transfusion is one
that requires multiple pieces of clinical and laboratory-
based information. Typically, intraoperative blood volume
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replacement is done by the anesthesiologist, but commu-
nication with the surgical team is critical. In making this
decision, multiple factors are considered including the
patient’s hemodynamic status, cardiovascular disease sta-
tus, hemoglobin concentration, hematocrit, the estimated
blood loss, and the perceived rate of blood loss [2].
Blood transfusions have been shown to suppress the
immune system in a number of ways, including impaired
natural killer cell cytotoxicity [4] and lymphocyte activity
[5]. The immunomodulatory effects of transfusions were
first highlighted clinically by Opelz et al. when they
showed improved survival of kidney transplant grafts
with increasing number of pretransplant transfusions
[6]. There has been a number of observational, retro-
spective studies showing association between blood
transfusion and infectious complications [7–10], as well
as early cancer recurrence [11–13]. A 2012 Cochrane
review of 36 studies demonstrated an increased odds
ratio of 1.42 (95 % CI, 1.20 to 1.67) for recurrence of
colorectal cancer in patients receiving perioperative
blood transfusions [12]. Despite this, there is much con-
flicting evidence in the literature pertaining to blood
transfusions and cancer recurrence. This remains an
area where blood transfusions have a perceived negative
consequence without high-quality evidence to support
such a claim.
Blood transfusions are administered to approximately
one third of patients undergoing liver resections [14–18],
and this rate appears to be decreasing over time. In a
series of 1351 patients undergoing liver resection for colo-
rectal liver metastases between 1986 and 2001 at a single
center, Kooby et al. found that 55 % of patients received a
blood product transfusion (red blood cells, platelets, or
plasma) either intraoperatively or during their postopera-
tive hospitalization [10]. They also demonstrated a reduc-
tion in the use of blood products over time, with 83 % of
patients between 1986 and 1990, 54 % of patients between
1991 and 1994, and 43 % of patients between 1995 and
2001 receiving blood. They found that non-transfused
patients experienced fewer serious postoperative compli-
cations (33 vs 46 %) and that patients transfused more
than 2 units of blood experienced more complications
than those transfused 1 or 2 units (51 vs 42 %). Blood
transfusion remained a significant predictor of complica-
tion after multivariate analysis (OR 1.5), along with larger
resections and male gender. Blood transfusion was also
found to be an independent predictor of 60-day mortality
on multivariate analysis (OR 3.7), but not to have a signifi-
cant impact on long-term survival beyond the 60-day
postoperative period. More recent data demonstrates that
the trend towards less blood transfusion continues. In a
study of 2448 patients undergoing liver resection in 2013,
the rate of blood transfusion for the entire cohort was
22.1 % [19].
Objective
The primary objective of this review is to synthesize the
evidence surrounding the prevalence and impact of
intraoperative and postoperative transfusions of allogen-
eic red blood cells on key clinical outcomes in patients
undergoing liver resection. The key clinical outcomes of
interest include transfusion prevalence, postoperative
mortality, postoperative morbidity (infectious complica-
tions, liver failure, acute renal failure, cardiovascular and
cerebrovascular events, and thromboembolic events),
and long-term overall and disease-free survival.
Methods/design
Our systematic review was designed using the Preferred
Reporting Items for Systematic Review and Meta-Analyses
(PRISMA) guidelines [20]. A PRISMA-Protocol checklist
was followed (see Additional file 1). The protocol has been
registered with the PROSPERO International Prospective
Register of Systematic Reviews (CRD42015026132).
Eligibility criteria
Population
The population of interest is adult patients, over the age
of 18, undergoing elective liver resection for any indica-
tion. This does not include patients having emergency
liver resection for trauma or bleeding. It does include
patients undergoing partial liver resection in order to be a
transplant donor but does not include patients receiving
liver transplants. Studies that include liver resection in
addition to other procedures will be included if the liver
resection data can be extracted from the rest, either from
the paper directly or through communication with the
corresponding author.
Intervention
The intervention being studied is the administration of
allogeneic red blood cell transfusions during the liver
resection (intraoperative), or during the immediate
hospitalization following liver resection (postoperative).
This review will not focus on the administration of other
types of blood products, such as autologous transfu-
sions, platelets, plasma, or cryoprecipitate.
Comparators
Any randomized controlled trial (RCT) or observational
cohort study comparing patients who received red blood
cell transfusions to those who did not will be included in
this review.
Outcomes
The outcomes of interest include transfusion prevalence,
postoperative mortality, postoperative morbidity, and
long-term cancer survival outcomes. As postoperative
mortality can be defined at a number of time points, all
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will be acceptable and will be categorized and described
in the review. Postoperative morbidities that will be
included are overall morbidity, infectious complications
(surgical site infection, pneumonia, urinary tract infection),
acute liver failure/insufficiency, acute renal failure,
cardiovascular events, cerebrovascular events, and
thromboembolic events. Severity of complications will be
considered and categorized in subgroups, using the
Clavien-Dindo classification, if available from the reported
data. Long-term cancer survival outcomes will include
overall survival and disease-free survival, as well as disease
recurrence. Studies that report any, or all, of these out-
comes will be considered for inclusion.
Search strategy
The search strategy was created by the primary investiga-
tor (SB) and an expert medical librarian (RS). The Medline
(1946–present), Embase and Embase Classic (1947–
present), and the Cochrane Central Register of Con-
trolled Trials will be searched from inception until
September 2015 for articles using a combination of
MESH and text words for liver resection and blood
transfusion (see Additional file 2). Searches are
restricted to human studies with adult (>18 years old)
patients. Study inclusion will be limited to titles writ-
ten in English or French. Reference lists will be
reviewed for additional studies. Gray literature and
conference proceedings will not be searched specifically,
although abstracts identified in the search strategy will be
considered for inclusion to minimize the impact of publi-
cation bias. To avoid duplicate study selection, author
names will be compared, and if there is uncertainty, corre-
sponding authors will be contacted.
Study selection
After a pilot screening evaluation conducted by two
independent investigators (SB and LB) of 100 titles and
abstracts to establish excellent agreement (kappa > 0.75),
one investigator (SB) will conduct the initial title and
abstract screen for the remainder. Two investigators (SB
and LB) will then conduct the full text review to identify
studies meeting inclusion/exclusion criteria. Disagree-
ments will be resolved via consensus where possible, and
by a third reviewer, if necessary (GM).
Data extraction
Two investigators (SB and LB) will extract data in
duplicate from the included studies into a spreadsheet
developed a priori. Data will include publication
details, study design, study size, patient demographics,
outcomes used, confounding variables controlled for on
multivariate analysis, and effect of treatment on outcomes.
Quality assessment
Two investigators (SB and LB) will independently assess
the included studies for risk of bias and quality of
reporting. Disagreement will be resolved via consensus
or a third investigator, when necessary. The included
studies are expected to all be observational cohort stud-
ies, with no RCTs. Should there be any RCTs, they will
be assessed using the Cochrane Handbook “Risk of Bias”
assessment tool [21]. The observational cohort studies
will be assessed using the Cochrane Risk of Bias Assess-
ment Tool for Non-Randomized Studies of Interventions
(ACROBAT-NRSI) [22]. This will evaluate risk of bias
due to confounding, selection, measurement, and inter-
pretation. The quality of reporting will be assessed using
the strengthening the reporting of observational studies
in epidemiology (STROBE) checklist [23].
Data synthesis
The data will be entered and interpreted into a narrative
synthesis. The narrative synthesis will be grouped by
outcome of interest (postoperative mortality, postopera-
tive morbidity, and long-term cancer outcomes). Within
each outcome group, the studies will be subgrouped by
liver pathology (primary liver tumors, metastatic disease,
and donor hepatectomy), as these each have their own
distinct clinical characteristics when it comes to blood
transfusion. Other subgroupings of interest may include
date of publication, methodological quality, and extent
of adjustment for confounding.
It is unlikely that a quantitative meta-analysis will be
feasible due to expected lack of controlled clinical trials
and clinical and statistical heterogeneity; however, this
will be considered once the data is collected. Where
possible, given the availability of data, and the clinical
and statistical homogeneity, a quantitative meta-analysis
of observational studies may be performed. If a meta-
analysis is possible, the effect of blood transfusion will
be stratified by outcome, using a random effects model.
We will also evaluate the impact of important clinical
and methodological characteristics through the conduct
of subgroup analyses. Planned subgroup analyses include
indication for surgery (benign, primary malignant, meta-
static), risk of bias score, and method of multivariate
analysis. We will also explore sources of potential
heterogeneity through visual inspection of overall pooled
analyses and inspection of Q and I2 statistics. Quanti-
tative meta-analysis will be performed using OpenMetaA-
nalyst software (Brown University, School of Public
Health).
Discussion
There have been a number of recent calls for guidelines
on the appropriate use of blood transfusions during liver
resection [1, 24]. Given the potential life-saving benefit
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of blood transfusions, as well as the possibility of nega-
tive clinical consequences when given inappropriately,
this is an important future direction. While general
guidelines on perioperative blood management do exist
[25], none are specific to liver surgery. Furthermore,
there is published evidence of practice variability in the
use of blood conservation methods during liver resection
[26], as well as in the use of blood transfusions during
liver transplant [27].
A thorough synthesis of the current body of literature
is a necessary initial step in this process. One previous
systematic review and meta-analysis showed blood
transfusions had increased postoperative mortality,
postoperative morbidity, and cancer recurrence after
liver resection but only studied patients with hepato-
cellular carcinoma [28]. The proposed review will
expand the patient population to include patients
undergoing liver resection for all indications, in particular
for colorectal liver metastases, which is the most common
indication for liver resection in North America [19, 29].
Furthermore, this previous review included studies up
until 2012, and an update to include the past three years
of literature will be important.
The strengths of the proposed systematic review will
be a very broad search strategy, rigorous inclusion/exclu-
sion criteria, a focus on only studies where blood trans-
fusion is the primary intervention of interest, and the
inclusion of all indications for elective liver resection.
Limitations of this review will likely include a lack of
RCTs and significant clinical and statistical heterogeneity
between studies. This will likely prevent the conducting
of a quantitative meta-analysis.
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